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Abstract 
a) Objectives: International guidance recommends that early serial sampling of high sensitivity 
troponin be used to accurately identify acute myocardial infarction (AMI) in chest pain patients. 
The background evidence for this approach is limited. We evaluated whether on presentation and 
4-hour high-sensitivity troponin I (hs-cTnI) could be used to accurately rule-out AMI.  
b) Design and Methods: hs-cTnI was measured on presentation and at 4-hours in adult patients 
attending an emergency department with possible acute coronary syndrome. We determined the 
sensitivity for AMI for at least one hs-cTnI above the 99th percentile for a healthy population or 
alone or in combination with new ischemic ECG changes. Both overall and sex-specific 99th 
percentiles were assessed.. Patients with  negative tests were designated low-risk. 
c) Results: 63 (17.1%) of 368 patients had AMI.  The median (interquartile range) time from 
symptom onset to first blood sampling was 4.8 hours (2.8-8.6). The sensitivity of the 
presentation and 4h hs-cTnI using the overall 99th percentile was 92.1% (95% CI 82.4% to 
97.4%) and Negative Predictive Value 95.4% (92.3% to 97.4%) with 78.3% low-risk. Applying 
the sex-specific 99th percentile did not change the sensitivity. The addition of ECG did not 
change the sensitivity.  
d) Conclusion: Hs-cTnI >99th percentile thresholds measured on presentation and at 4-hours was 
not a safe strategy to rule-out AMI in this clinical setting irrespective of whether sex-specific 
99th percentiles were used, or whether hs-cTnI was combined with ECG results. 
 
 
Key Words:  high sensitivity troponin; acute myocardial infarction; emergency department; 
emergency room; accelerated diagnostic pathway; acute coronary syndrome; STEMI; NSTEMI 
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1. Introduction 
Twin imperatives drive the assessment of patients presenting with chest pain to Emergency 
Departments (ED), namely early identification of patients with an acute myocardial infarction 
(AMI) and early identification of those at very low short-term risk of harm from AMI or 
ischemic heart disease. The former facilitates earlier planning of treatment and the latter helps 
avoids unnecessary inpatient admissions. Historically, most patients with symptoms suggestive 
of AMI undergo prolonged assessment, either in the ED or as hospital in-patients even though 
three quarters of these patients ultimately do not have a final diagnosis of AMI[1-3]. 
 
High sensitivity cardiac troponin assays (hs-cTn) produce analytically reliable results at the 99
th
 
percentile of a healthy population which may facilitate identification of patients suitable (i.e. 
safe) for rapid discharge to outpatient care with potentially major benefits for health services 
costs and ED and hospital overcrowding[4-7]. A second measurement of hs-cTn from a blood 
sample drawn two to four-hours after hospital attendance time-point may be useful. Whereas 
accelerated chest pain pathways incorporating presentation and 2h sampling can identify an 
increased proportion of low-risk patients[8,9] a presentation and 3h or 4h timeframe is still short 
enough so that patients could remain in the ED under the care of the original clinicians without 
transfer to another hospital area or handover to other staff. 
 
The 2011 European Society of Cardiology (ESC) guidelines for management of acute coronary 
syndrome without persistent ST-segment elevation recommended a rapid rule-out of AMI 
protocol with only serial sampling of high sensitivity cardiac troponin[10]. A presentation and 3h 
sampling time was proposed based on two studies, one utilised a small sample size and the other 
utilised only one sample per patient[11,12]. An earlier generation troponin assay had yielded no 
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statistical difference in the positivity for AMI using greater than 3h or greater than 6h between 
samples[1,13,14]. The 2011 guidelines additionally recommended that where both troponin 
values are less than the 99
th
 percentile of a healthy population that the Global Registry of 
Coronary Events (GRACE) be applied to confirm low risk. Since publication of the ESC 
guidelines a study by Keller and colleagues in a cohort of patients presenting with chest pain 
found that a prototype high sensitivity cardiac Troponin I (hs-cTnI) at a 99
th
 percentile threshold 
of 30 ng/L had a 98.2% (95.9% to 99.4%) sensitivity for AMI with serial sampling at 
presentation and 3h[5].   
 
The more recent National Institute for Health Care and Excellence (NICE) diagnostics guidance 
for hs-cTn assays recommending that “the assays are recommended for use with early rule-out 
protocols, which typically include a blood sample for cardiac troponin I or T taken at initial 
assessment in an emergency department and a second blood sample taken after 3 hours”. Also 
recommended is that the high sensitivity troponin be used in conjunction with electrocardiogram 
(ECG) for diagnosis of NSTEMI[15].  
 
We aimed to prospectively validate that plasma troponin levels analysed with a hs-cTn assay at 
presentation (0h) and 4h from hospital presentation can rule-out AMI in patients presenting 
acutely to Emergency Departments with chest discomfort that might be due to an AMI. We 
assessed both the troponin alone (ESC) and troponin plus ECG (NICE) strategies. For each 
strategy we also compared the performance of overall 99
th
 percentile to the sex-specific 
percentiles. Additionally, we assessed the sensitivity for AMI and the proportion of patients who 
could be designated as low risk for AMI when the threshold used was the limit of detection of 
the high sensitive troponin.  
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2. Methods 
An observational cohort study design was used. Patients were recruited in conjunction with a 
randomised controlled trial comparing an ‘accelerated’ (2 hour) chest pain diagnostic pathway 
against the standard investigative process at Christchurch Hospital. This trial has been described 
in detail elsewhere[8] and was carried out in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki) for experiments involving humans, received 
regional ethics approval and was registered on anzctr.org.au as ACTRN12610000766011. 
Briefly, eligible patients were aged ≥18 years, presenting acutely from the community to the ED 
with symptoms suggestive of AMI for whom, following initial clinical assessment the attending 
physician(s) planned to investigate for AMI with serial biomarker tests. In accordance with 
American Heart Association case definitions, possible cardiac symptoms included: the presence 
of acute chest, epigastric, neck, jaw or arm pain or discomfort or pressure without apparent non-
cardiac source[2].  Patients were excluded if any of the following conditions were satisfied: ST 
Segment Elevation Myocardial Infarction (STEMI) as demonstrated by an ST elevation on any 
electrocardiograph (ECG) at presentation (Note: patients with all other ECG changes, including 
ST depression, were included); chest pain episode began >12 hours prior to assessment, proven 
or suspected non-coronary pathology as the cause of chest pain; need for admission regardless of 
a cTn <99
th
 percentile, due to other medical conditions, or need for other investigations; 
previously enrolled in this study; anticipated problem with follow-up (e.g. resident outside New 
Zealand or terminal illness); or unable or unwilling to provide informed consent.  Enrolment was 
consecutive during the hours of available research nurse (normally 0800 to 2300, 7 days a week). 
This analysis was limited to patients with sufficient stored plasma sample available for hs-cTnI 
assay at both presentation and 4 hours. 
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2.1 Reference standard 
Classification of AMI was based upon global taskforce recommendations requiring evidence of 
myocardial necrosis together with evidence of myocardial ischaemia (ischaemic symptoms, ECG 
changes or imaging evidence)[4] Necrosis was diagnosed on the basis of a rising or falling 
pattern of the laboratory cardiac troponin (ARCHITECT troponin I [TnI] assay; Abbott) level, 
with at least one value above the 99th percentile (28 ng/L). The manufacturer-specified LOD for 
the assay was 10 ng/mL, and 10% coefficient of variation was at 32 ng/L.  Outcomes and 
investigations were reported using predefined standardised reporting guidelines[16]. The 
presence of AMI was adjudicated independently by local cardiologists using these reporting 
guidelines and blinded to the results of the hs-cTnI (index test). If the reference troponin was 
above the reference range, but there was no rise or fall, other causes of a raised troponin were 
considered. If no clear alternative cause of the troponin rise was apparent then, if the clinical 
presentation was suggestive of ACS, an adjudicated diagnosis of AMI was made. A panel of two 
cardiologists performed the adjudication independent of each other with a third cardiologist 
making an independent adjudication in cases of disagreement. 
2.2 Index Tests 
Hs-cTnI sampling was on presentation to the ED and 4 hours later. Blood was drawn into 1x4mL 
Lithium heparin tubes, spun at 3220 RCF at 4°C for 10 minutes, 1ml of plasma was then 
transferred to one or two 1.5mL tubes and immediately stored at -80°C for later thawing and 
assay. Samples were assayed 12 to 36 months following collection. An ischaemic ECG was 
defined as ST-segment depression of at least 0.05 mV in 2 or more contiguous leads (including 
reciprocal changes), T-wave inversion of at least 0.1 mV, or Q-waves >30 ms in width and 
greater than or equal to 0.1 mV in depth in at least 2 contiguous leads. Patients with other 
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abnormal ECG findings (eg, pacing artefact and left bundle-branch block) that were present on 
pre-existing ECGs were not defined as high risk. The troponin assay used for the index test was 
the Abbott Architect Stat high sensitivity troponin I (hs-cTnI). It has a limit of detection (LOD) 
of 2 ng/L, 10% CV at 5 ng/L (Limit of Quantitation LoQ), sex-specific 99
th
 percentile of 16 ng/L 
for women and 34 ng/L for men, and overall 99
th
 percentile of 26 ng/L (Manufacturer provided 
thresholds).  Assessment of five risk stratification strategies was performed where low-risk was 
defined as: 
(i) presentation and 4h hs-cTnI values less than the overall 99th percentile, 
(ii) presentation and 4h hs-cTnI values less than the sex-specific 99th percentiles, 
(iii) no ischemic changes on ECG and presentation and 4h hs-cTnI values less than the 
overall 99
th
 percentile, 
(iv) no ischemic changes on ECG and presentation and 4h hs-cTnI values less than the 
sex-specific  99
th
 percentiles, and 
(v) no ischemic changes on ECG and presentation (only) hs-cTnI less than the LOD. 
 
Demographics of the sample were reported using standard descriptive statistics. For each 
strategy, the sensitivity, specificity, negative predictive value, and positive predictive value were 
reported for AMI. For each strategy we determined the proportion of patients identified as low 
risk for AMI. We further calculated the GRACE score for false negatives and took a score <140 
to confirm the classification as low-risk according with the ESC guidelines. All confidence 
intervals presented are exact binomial 95% confidence intervals. All calculations were made in 
R[17]. 
 
3. Results 
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There were 368 patients. The first blood sample was taken a median (interquartile range) 4.8 
(2.8-8.6) hours after onset of symptoms. The median time difference between the presentation 
and the 4h sample was 4.4 h (4.25 to 4.63).  Sixty-three (17.1%) were diagnosed with AMI. 
Demographics are given in table 1. 
Table 1: Cohort characteristics 
Variable Value 
Age (years) 61±13 
Female  35% (129) 
Weight (kg) 85±19 
Ethnicity (self identified)  
Maori 9 
New Zealander/ New Zealand European 329 
Other  30 
Risk Factors and History (patient 
reported)  
  Hypertension  36.8% (174) 
  Dyslipidaemia  53.8% (198) 
  Diabetes  16.0% (57) 
  Current smoker  18.5% (68) 
  Family history of Ischemic Heart Disease  60.3% (222) 
Prior:   
  Myocardial Infarction 26.6% (98) 
  Angina  37.0% (136) 
  Ventricular Tachycardia 4.6% (17) 
   CAD 44.0% (162) 
  Atrial Arrhythmia 9.5% (35) 
  Congestive Heart Failure 4.3% (16) 
  Stroke or Transient Ischemic Attack 11.1% (41) 
  Peripheral Arterial Disease 4.6% (17) 
  Coronary Artery Bybass Graft  7.6% (28) 
  Coronary Angioplasty  27.7% (102) 
  Rheumatoid Arthritis  2.2% (8) 
Outcomes  
  ECG positive 5.4% (20) 
  STEMI 1 (0.3%) 
  NSTEMI 62 (16.8%) 
  Hospital length of stay (Days) 1.2 (0.9-3.1) 
  
Data presents as n (%) or mean±SD or median (lower quartile - upper quartile) 
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The sensitivity for AMI of presentation and 4h hs-cTnI only using the overall 99
th
 percentile was 
92.1% (95% CI: 82.4% to 97.4%) with 78.3% identified as low risk. The Negative Predictive 
Value (NPV) was 98.3% (96.0% to 99.4%); Table 2.  The five false negatives were all male. 
Their GRACE score was <140 in all cases confirming they were considered low-risk by this 
algorithm. Three showed increase in hs-cTnI of >10 ng/L between samples; symptom onset time 
was more than 3 hours prior to the first blood sample in three cases, Table 3.  
 
The sensitivity for AMI and other metrics were the same for the sex-specific 99
th
 percentile 
thresholds. The addition of ECG did not change the sensitivity for the test.  The sensitivity was 
100% (91.6% to 100%) for the LoD as threshold, with 11.4% identified as low-risk. 
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Table 2:  Diagnostic metrics for each index test 
Tests  
AMI 
Not 
AMI 
Proporti
on Low 
Risk (%) 
Sensitivity 
(%) 
Specificity 
(%) 
Negative 
Predictive 
Value (%) 
Positive 
Predictive 
Value (%) 
(i) Presentation and 
4h hs-cTnI > overall 
99
th
 Percentile  
Test 
positive 
58 22 
78.3 92.1 
(82.4 to 97.4) 
92.8 
(89.3 to 95.4) 
95.4 
(92.3 to 97.4) 
74.2 
(62.0 to 84.2) 
Test 
negative 
5 283 
(ii) Presentation and 
4h hs-cTnI > sex 
specific 99
th
 
Percentile 
Test 
positive 
58 22 
78.3 92.1 
(82.4 to 97.4) 
92.8 
(89.3 to 95.4) 
95.4 
(92.3 to 97.4) 
74.2 
(62.0 to 84.2) 
Test 
negative 
5 283 
(iii) ECG + 
Presentation and 4h 
hs-cTnI > overall 99
th
 
Percentile  
Test 
positive 
58 25 
77.4 92.1 
(82.4 to 97.4) 
91.8 
(88.1 to 94.6) 
98.2 
(96.0 to 99.4) 
69.9 
(58.8 to 79.5) 
Test 
negative 
5 280 
(iv) ECG + 
Presentation and 4h 
hs-cTnI > sex 
specific 99
th
 
Percentile 
Test 
positive 
58 25 
77.4 92.1 
(82.4 to 97.4) 
91.8 
(88.1 to 94.6) 
98.2 
(96.0 to 99.4) 
69.9 
(58.8 to 79.5) 
Test 
negative 5 280 
(v) ECG + 
Presentation hs-cTnI 
>Limit of Detection 
(2 ng/L) 
Test 
positive 
63 263 
11.4 100 
(91.6 to 100) 
13.8 
(10.1 to 18.2) 
100 
(87.7 to 100) 
19.3 
(15.2 to 24.0) 
Test 
negative 
0 42 
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Table 3:  Details of the False Negatives for index test (i) Presentation and 4h hs-cTnI > 
overall 99th Percentile 
Study ID CP150 CP157 CP170 CP464 CP530 
sex M M M M M 
age 47 73 84 72 69 
Hs-cTnI at presentation (ng/L) 7.2 13.8 6.5 7.1 7 
Hs-cTnI at 4h (ng/L) 17.9 24.1 23 8.3 8.3 
cTnI (ng/L) at presentation <10 <10 <10 10 20 
First cTnI (ng/L) at >6h 60 120 30 20‡ 40 
ECG Negative Negative Negative Negative Negative 
Relative difference (%) 148.6 74.6 253.8 16.9 18.6 
Absolute difference (ng/L) 10.7 10.3 16.5 1.2 1.3 
Time from symptom onset to 
presentation sample (h) 
2.58 4.83 2.83 3.75 5.92 
Heart rate (bpm) 82 58 60 70 70 
Systolic blood pressure 121 126 160 124 190 
Creatinine (μmol/L) 130* 81 91 148** 65 
Killip Class NA 1 2 1 NA 
GRACE score (Death or MI in hospital) <133† 101 124 113 <132† 
Pain      
 Pleuritic No No No No Yes 
 On palpitation No No No No No 
 Radiates to arm No No Yes Yes No 
 Diaphoresis Yes Yes Yes Yes No 
Risk Factors and History (patient 
reported) 
     
  Hypertension  Yes Yes Yes No No 
  Dyslipidaemia  Yes Yes Yes Yes No 
  Diabetes  No Yes No No No 
  Current smoker  No No No No No 
  Family history of Ischemic Heart 
Disease  
Yes Yes Yes Yes No 
 Use of Aspirin in last 7 days No No No Yes No 
Prior:       
  Myocardial Infarction No No Yes Yes No 
  Angina  No Yes Yes Yes No 
  Ventricular Tachycardia No No No No No 
   CAD No Yes Yes Yes No 
  Atrial Arrhythmia No No No Yes No 
  Congestive Heart Failure No No No No No 
  Stroke or Transient Ischemic Attack No No Yes Yes No 
  Peripheral Arterial Disease No Yes No No No 
  Coronary Artery Bybass Graft  No No No No No 
  Coronary Angioplasty  No No Yes Yes No 
  Rheumatoid Arthritis  No No No No No 
Modified TIMI risk score†† 0 3 3 3 1 
Investigations and Treatments      
  Revascularisation 
Urgent PCI 
at 3 days 
Urgent 
CABG at 12 
days 
No No Urgent 
PCI at 6 
days 
  Angiostenosis Yes None None Yes Yes 
  Echocardiogram ejection fraction NA 62 36 62 65 
  EMRA NA No Yes No Yes 
* Possibly Acute Kidney Injury; **Probably a chronic elevation given the patient creatinine history. 
† Assumes a maximum Killip class of 3 because class 4 is cardiogenic shock and this was not recorded in any case. 
†† modified because the score for the troponin and ECG are not included. 
‡ a subsequent troponin on the next morning (13 hours later) was 40 ng/L (ie positive). 
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NA: Not Available; PCI: Percutaneous Coronary Intervention; MI: Myocardial Infarction; EMRA:  
Echocardiograph regional wall motion abnormality 
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4. Discussion 
The sensitivity for AMI of either presentation and 4h hs-cTnI at the 99
th
 percentile on its own or 
in combination with ECG on presentation to rule-out AMI was considerably less than 99%, a 
threshold considered optimal by ED physicians[18]. Even at the best sensitivity for AMI the 
upper confidence interval of 97.4% was below this level.  Notably this is less than the 98.2% 
(95.9% to 99.4%) found by Keller and colleagues for presentation and 3h hs-cTnI above the 99
th
 
percentile for a prototype hs-cTnI assay and without the inclusion of ECG in the test (the 
inclusion of which should only increase sensitivity). This and the false negatives we observed 
highlights the dangers of a biomarker only approach, especially where a relatively high threshold 
(99
th
 percentile of a healthy population) is applied and that findings during clinical assessment 
must be incorporated into the assessment in a Baysean manner together with biochemical 
markers. Previously, we have demonstrated in the primary trial that a minimum level of 99% 
sensitivity for AMI may be reached with risk stratification using the Thrombolysis in Myocardial 
Infarction (TIMI) risk score in addition to a presentation ECG and presentation and 2 hour 
contemporary cardiac troponin[8]. The TIMI score incorporates age, risk factors including 
family history of coronary artery disease, and history.  Other risk scoring strategies that may also 
improve identification of a low-risk cohort, for example the EDACS, HEART, Modified 
Goldman and Vancouver Chest Pain rule, include the same class of factors with different 
weightings and variation in the components that make up the history and risk factor scores in 
particular[9,19-21]. EDACS also includes sex. An EDACS-ADP may classify with high 
sensitivity over 40% of patients[9]. 
 
We also noted that in three of the false negatives there was a small, but measureable change in 
hs-cTnI of greater than 10 ng/L between samples.  Although both samples remained below the 
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99
th
 percentile, a cautious clinician may not wish to classify these patients as low risk.  Further 
work is needed to decide on the role of deltas below the 99
th
 percentile.  
 
The ESC guideline recommendation of a presentation and typically after 3h high sensitivity 
troponin samples to rule out AMI are based on only two studies. The first assessed the 
performance of hs-cTnT with a threshold of 14 ng/L in a population of 57 patients without 
impaired renal function and with retrospectively confirmed unstable angina and evolving 
NSTEMI[11].  A sensitivity of 100% for diagnosis of NSTEMI with a wide confidence interval 
(95% confidence interval: 75.1% to 100%) was achieved for serial sampling on admission and a 
second sample within 3 hours. The second study was comprised of two cohorts where the 
performance of a single hs-cTnT measure within a median 3 hours (range 0 to 7 hours) was 
assessed.  Only in one cohort, the Bad Nauheim ACS registry comprising 1023 patients who had 
been referred for coronary angiography or percutaneous coronary intervention (because of ACS 
within the previous 48 hours), was the performance of hs-cTnT assessed for diagnosis of 
AMI[12]. The sensitivity for AMI was 96% and negative predictive value 80%. Both these 
studies were published at a time when they may have been affected by the calibration issues 
leading to inaccurate reporting of numerical results for hs-cTnT[22,23]. 
 
The NICE guidelines were based on a systematic review of the literature which was dominated 
by hs-cTnT rather than hs-cTnI studies[24] and only 6 studies which reported multiple testing.  
The recommendation of a second hs-cTn test ‘typically’ at 3-hour time point was based on 
consideration of the possibility of ruling in AMI with a suitable delta. 
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This present study aimed to employ a 4-hour time period between presentation and the second 
sample. This was deliberate because the primary study already had presentation and 2 hour time 
points, 4 hours was still short enough to enable discharge from ED to outpatient care within the 
national 6 hour ED target stay, and was only likely to enhance sensitivity and specificity for AMI 
over a 3 hour sampling. The study was limited by its size meaning the confidence intervals are 
broad.  
 
Eggers and colleagues have previously considered the use of the 99th percentile for consecutive 
presentation and 2-hour hs-cTnI samples in combination with ECG to rule-out NSTEMI[25].  
They found the sensitivity for NSTEMI to be 96.9%; as with the current study, too low to be 
clinically useful. When the authors considered the lower 97.5% threshold (15.5 ng/L) the 
sensitivity for NSTEMI improved to 98.2% with 54.4% ruled-out by this strategy. Similarly the 
TRAPID AMI protocol employing an hs-cTnT threshold less than the 99
th
 threshold (ie 12 ng/L) 
along with a delta of <3 ng/L in 1 hour ruled out 60% of patients with 100% sensitivity in a 
derivation cohort[26] and 59.5% of patients with 99.6% sensitivity in a validation cohort[27]. 
Cullen and colleagues assessed the sensitivity for 30-d AMI or cardiac death of a Siemens 
contemporary troponin I at the 99
th
 percentile (56 ng/L) at 0 and 2h and found a sensitivity of 
92.2% [28].  Druey and colleagues also recently assessed the use of contemporary troponin I to 
rule-out AMI using a 0 and 2h algorithm with a lower threshold of 10ng/L[29]. This ruled-out 
44% of patients with a sensitivity of 98.4% in a derivation cohort and 62% of patients with a 
sensitivity of 94.5% in a validation cohort. The present study was not powered to discover an 
optimal threshold for rule-out.  Nevertheless, we could rule-out 58% of patients with 100% 
sensitivity (95%CI: 91.6% to 100%) for AMI with a threshold of 8 ng/L.  The differences are 
probably due to differences in cohort characteristics and because the current study had only 63 
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AMI resulting in broad confidence intervals. Nevertheless, the Eggers analysis and the present 
study suggest that a threshold between the limit of detection and 99
th
 percentile may be used with 
serial samples and in combination with ECG to rule-out a significant proportion of patients. We 
recommend that such strategies be compared in the same cohort with those which also utilise a 
risk stratification score. 
 
The use of an undetectable hs-cTnT [30,31] or hs-cTnI [5,32] in conjunction with a negative 
ECG has recently been demonstrated to rule-out AMI on presentation with excellent sensitivity.  
This study supports those findings with a sensitivity for AMI of 100% allowing 11.4% of 
patients to be ruled out of having an AMI shortly after presentation to ED.  In a cohort of patients 
with identical exclusion and inclusion criteria Greenslade and colleagues also had 100% 
sensitivity for AMI for undetectable hs-cTnI and found 17.8% of patients were low risk[15,32]. 
Similarly Keller and colleagues had a 100% sensitivity with 27.4% low risk[5,15]. On the other 
hand Body and colleagues found AMI could not be excluded by this method (sensitivity: 97.1%) 
and recommended further work on serial sampling to improve sensitivity[33]. Although the 
sensitivity for AMI in our study was 100%, the study size was limited and the lower limit 95% 
confidence intervals was only 91.6%. Therefore, we too recommend further work.   
 
A limitation of our study potentially affecting our conclusion that performance did not differ 
with sex-specific thresholds was that the diagnosis of AMI was based on overall (not sex-
specific) values. This may have biased against females with low, but abnormal troponin 
elevations using sex-specific cut points. 
 
5. Conclusion 
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The sensitivity for AMI of hs-cTnI <99
th
 percentile at presentation and 4 hours alone or in 
combination of a non-ischaemic ECG was too low to be reliably clinically useful for rule out 
when used without reference to clinical indicators. The proposed use of classifying patients with 
hs-cTnI less than the limit of detection on presentation also had good sensitivity and would 
enable approximately 10% of patients to be classified as low-risk as soon as the first blood 
results became available. 
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Highlights 
 
 AMI can not be ruled out by serial hs-cTnI <99th percentile within the ED 
 Sex-specific 99th percentile thresholds do not improve sensitivity 
 The addition of negative ECG does not improve sensitivity 
 11% may be ruled out with hs-cTnI <LoD and negative ECG 
